The peptide somatostatin (SRIF) has important physiological effects, mostly inhibitory, which have formed the basis for the clinical use of SRIF compounds. SRIF binding to its 5 guanine nucleotide-binding proteins-coupled receptors leads to the modulation of multiple transduction pathways. However, our current understanding of signaling exerted by receptors endogenously expressed in different cells/tissues reflects a rather complicated picture. On the other hand, the complexity of SRIF receptor signaling in pathologies, including pituitary and nervous system diseases, may be studied not only as alternative intervention points for the modulation of SRIF function but also to exploit new chemical space for drug-like molecules.
|Autori interni:||BAGNOLI, PAOLA|
|Autori:||CERVIA D; BAGNOLI P|
|Titolo:||An update on somatostatin receptor signalling in native systems and new insights on their pathophysiology|
|Anno del prodotto:||2007|
|Appare nelle tipologie:||1.1 Articolo in rivista|